Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates

Molecular Pharmacology

Volumn 77, Issue 2, 2010, Pages 262-269

  Masaike, Yuka ^a   Takagi, Takeshi ^a   Hirota, Masataka ^a   Yamada, Joe ^a   Ishihara, Satoru ^a   Yung, Tetsu M C ^a   Inoue, Takamasa ^a   Sawa, Chika ^b   Sagara, Hiroshi ^c   Sakamoto, Satoshi ^a   Kabe, Yasuaki ^a   Takahashi, Yasuyuki ^d   Yamaguchi, Yuki ^a   Handa, Hiroshi ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Research Association for Biotechnology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DYNAMIN II; GUANOSINE TRIPHOSPHATASE;

ADENOVIRUS INFECTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENDOCYTOSIS; MOUSE; NONHUMAN; OSTEOPOROSIS; PRENYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CATTLE; CELL LINE; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; DYNAMIN II; ENDOCYTOSIS; HELA CELLS; HUMANS; MICE; OSTEOPOROSIS; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION;

EID: 74549131774     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.059006     Document Type: Article

References (40)

1. Anderson HA, Chen Y, and Norkin LC (1996) Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Mol Biol Cell 7:1825-1834.
2. Artalejo CR, Lemmon MA, Schlessinger J, and Palfrey HC (1997) Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells. EMBO J 16:1565-1574.
3. Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, and Glenn JS (2002) A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 76:10465-10472.
4. Bruzzaniti A, Neff L, Sanjay A, Horne WC, De Camilli P, and Baron R (2005) Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity. Mol Biol Cell 16:3301-3313.
5. Catimel B, Yin MX, Schieber C, Condron M, Patsiouras H, Catimel J, Robinson DE, Wong LS, Nice EC, Holmes AB, et al. (2009) PI(3,4,5)P3 interactome. J Proteome Res 8:3712-3726.
6. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, and Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476.
7. Damke H, Baba T, Warnock DE, and Schmid SL (1994) Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 127:915-934.
8. Damke H, Muhlberg AB, Sever S, Sholly S, Warnock DE, and Schmid SL (2001) Expression, purification, and functional assays for self-association of dynamin-1. Methods Enzymol 329:447-457.
9. del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña JM, Rodríguez-Zapata M, Alvarez-Mon M, et al. (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200:541-547.
10. Dignam JD, Lebovitz RM, and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
11. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, and Coxon FP (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684-694.
12. Einav S and Glenn JS (2003) Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother 52:883-886.
13. Farassati F, Yang AD, and Lee PW (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3:745-750.
14. Frith JC and Rogers MJ (2003) Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18:204-212.
15. Glenn JS, Marsters JC Jr, and Greenberg HB (1998) Use of a prenylation inhibitor as a novel antiviral agent. J Virol 72:9303-9306.
16. Gower TL and Graham BS (2001) Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 45:1231-1237.
17. Heymann D, Ory B, Gouin F, Green JR, and Rédini F (2004) Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10:337-343.
18. Ishikawa C, Matsuda T, Okudaira T, Tomita M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T, and Mori N (2007) Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 136:424-432.
19. Lundmark R and Carlsson SR (2003) Sorting nexin 9 participates in clathrinmediated endocytosis through interactions with the core components. J Biol Chem 278:46772-46781.
20. Marks B, Stowell MH, Vallis Y, Mills IG, Gibson A, Hopkins CR, and McMahon HT (2001) GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature 410:231-235.
21. Mayor S and Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8:603-612.
22. Nakanishi A, Chapellier B, Maekawa N, Hiramoto M, Kuge T, Takahashi RU, Handa H, and Imai T (2008) SV40 vectors carrying minimal sequence of viral origin with exchangeable capsids. Virology 379:110-117.
23. Negredo E, Martínez-López E, Paredes R, Rosales J, Pérez-Alvarez N, Holgado S, Gel S, del Rio L, Tena X, Rey-Joly C, et al. (2005) Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 19:343-345.
24. Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, Palù G, and Göttlinger HG (2007) Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A 104:6812-6817.
25. Praefcke GJ and McMahon HT (2004) The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol 5:133-146.
26. Qaqish RB and Sims KA (2004) Bone disorders associated with the human immunodeficiency virus: pathogenesis and management. Pharmacotherapy 24:1331-1346.
27. Reszka AA, Halasy-Nagy JM, Masarachia PJ, and Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274:34967-34973.
28. Roelofs AJ, Thompson K, Gordon S, and Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s-6230s.
29. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, et al. (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209-257.
30. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, and Handa H (2009) Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec 9:66-85.
31. Schmid SL, McNiven MA, and De Camilli P (1998) Dynamin and its partners: a progress report. Curr Opin Cell Biol 10:504-512.
32. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, et al. (2000) High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18:877-881.
33. Soulet F, Yarar D, Leonard M, and Schmid SL (2005) SNX9 regulates dynamin assembly and is required for efficient clathrin-mediated endocytosis. Mol Biol Cell 16:2058-2067.
34. Stepensky D, Kleinberg L, and Hoffman A (2003) Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 42:863-881.
35. Sweitzer SM and Hinshaw JE (1998) Dynamin undergoes a GTP-dependent conformational change causing vesiculation. Cell 93:1021-1029.
36. Takei K, McPherson PS, Schmid SL, and De Camilli P (1995) Tubular membrane invaginations coated by dynamin rings are induced by GTP-gamma S in nerve terminals. Nature 374:186-190.
37. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, and Papapoulos SE (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805-811.
38. Wang K, Huang S, Kapoor-Munshi A, and Nemerow G (1998) Adenovirus internalization and infection require dynamin. J Virol 72:3455-3458.
39. Ylitalo R, Mönkkönen J, Urtti A, and Ylitalo P (1996) Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127:200-206.
40. Yun MH and Kwon KI (2006) High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J Pharm Biomed Anal 40:168-172.